Quick Facts

• Therapeutic Purpose: Contraception
• Main Function: Prevents pregnancy
• Patient Group: Women of reproductive age

---

Femvulen is a prescribed medication intended for use as a long-acting hormonal contraceptive. The primary application of this treatment is to assist in preventing pregnancy through a systemic therapeutic effect.

This medication provides a method of birth control designed to reduce the likelihood of conception. It is administered to women of reproductive age who seek a sustained, reversible form of contraception as part of family planning efforts. The treatment acts to influence the natural hormonal cycle, which contributes to its intended effect of preventing the release of an egg (ovulation) and changing the conditions within the reproductive system to make pregnancy less likely.

Clinically, this type of injectable hormonal therapy is utilized to offer protection against pregnancy over a defined period following administration. Physicians consider this option for individuals whose personal health needs align with this method of hormonal regulation.

Official Eligibility Profile: Who Can and Cannot Use Femvulen

Femvulen is a combined hormonal contraceptive indicated for use in females of reproductive potential who do not possess specific health conditions or risk factors defined as absolute contraindications in regulatory documentation.

Populations Who MUST NOT Use This Medicine (Contraindicated)

Use of Femvulen is strictly contraindicated if you have or have had any of the following conditions, as they significantly increase the risk of serious side effects, primarily thrombotic events:

• A history of or current venous or arterial thrombotic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or coronary artery disease.
• Uncontrolled hypertension or hypertension with existing vascular disease.
• Diabetes mellitus with vascular involvement.
• Migraines with aura (focal neurological symptoms).
• Smoking combined with being over age 35.
• Known or suspected breast cancer or other estrogen- or progestin-sensitive cancers.
• Liver tumors (benign or malignant) or active liver disease/hepatic impairment.
• Pregnancy or suspected pregnancy.

Conditional and Restricted Use

Femvulen is not recommended for women who are breastfeeding in the immediate postpartum period, as it may decrease milk production. Furthermore, use is generally restricted for at least four weeks after delivery for non-breastfeeding women due to high thromboembolism risk. Special consideration and monitoring are required for patients with certain conditions like well-controlled hypertension.

Interactions with other medicines and products

Femvulen, like other combination hormonal contraceptives, has documented interactions that can impact its effectiveness or increase the risk of adverse effects. These interactions are categorized based on their mechanism and the required clinical response as outlined in official regulatory documents.

Products That May Reduce Effectiveness

The primary category of interacting medicinal products are hepatic enzyme inducers. These medicines increase the breakdown of the hormones in Femvulen, leading to lower concentrations in the body and a risk of contraceptive failure. This requires the use of an alternative, non-hormonal method of contraception during co-administration and for a specified time after the enzyme inducer is stopped. The herbal supplement St. John’s Wort is also documented as an enzyme inducer and its use with Femvulen is advised against for the same reason.

Products with Contraindicated Use

Co-administration is contraindicated with specific combination drug regimens used to treat Hepatitis C Virus (HCV). These include regimens containing ombitasvir/paritaprevir/ritonavir pm dasabuvir, or those containing glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir. This restriction is mandated due to the potential for significant increases in the liver enzyme alanine aminotransferase (ALT) when these products are used together.

Other Documented Constraints

Official labeling requires the use of backup, non-hormonal contraception for the first seven days if the initiation of Femvulen occurs on a day other than the first day of the menstrual cycle, reflecting the time needed to establish contraceptive protection. Additionally, use of this medication may affect the levels of other drugs, such as lamotrigine, requiring dose adjustment of the co-administered drug.

The mechanism of action of Femvulen is defined by its ability to engage and modulate specific receptor and enzyme systems within key physiological pathways. This mechanism is defined by its specific engagement with targets.

Targeted Modulation of Receptor Systems

Femvulen exerts its primary effect by acting as a selective allosteric modulator at the X Receptor subtype. This engagement adjusts the receptor's sensitivity and capacity for signal transmission, thereby establishing a core influence on biological signaling. This process is relevant in systems where targeted pathway adjustment is required to influence regulatory processes within the physiological system.

Dampening of Molecular Signal Cascades

By modulating the X Receptor, Femvulen initiates a sequence of events that results in targeted interference within the downstream molecular cascade, specifically affecting the Y second messenger system. This action serves to suppress or limit signaling sequences that would otherwise lead to heightened or excessive physiological responses. This limits the impact of excessive mediator activity and contributes to a more regulated state within the targeted pathways.

Femvulen is a specific type of combined hormonal medicine provided as a sterile oil-based solution intended exclusively for administration via deep intramuscular (IM) injection into a large muscle, such as the gluteal or deltoid region. This administration route is required for the formulation to create a medication depot that enables the gradual, slow release of the active ingredients over a prolonged period.

Standard Dosing and Schedule

The standard pattern of use is a monthly cyclic regimen. The official dose is the complete contents of one single-use ampoule, with common strengths containing a combination such as 150 mg of Algestone Acetophenide and 10 mg of Estradiol Enantate.

The most critical component of the usage protocol is the timing of administration:

• Initial Dose Timing: The very first injection of Femvulen is typically given early in the menstrual cycle to help establish immediate protection. Common official timing windows for this initial dose include the first 5 days of the menstrual cycle, or a slightly later start between Days 7 and 10.
• Subsequent Dosing: All injections that follow the initial dose must be administered on a strict monthly schedule, usually designated as every 30 ± 3 days, regardless of the patient's bleeding pattern or cycle date. This fixed interval is essential to ensure continuous therapeutic levels are maintained.

The medication is designed for long-term, continuous administration for as long as contraception is required. Because the drug is not active by mouth, administration must be performed parenterally by a healthcare professional.

Research evidence / Overview of studies for Femvulen

This overview describes the types of clinical studies that were evaluated in research exploring the combined hormonal injectable known as Femvulen. It summarizes the specific outcomes researchers examined and highlights what remains uncertain in the current body of evidence, according to regulatory and scientific literature.

Evidence Overview: Studies for Pregnancy Prevention

The primary research for this formulation was evaluated in studies exploring contraception in women of reproductive age. The research base includes various randomized and non-randomized multicenter clinical trials, along with extensive observational studies and analyses of post-marketing experience. Researchers examined outcomes related to pregnancy rates using specific metrics like the Pearl Index. They also explored fundamental hormonal effects through dedicated pharmacodynamic studies focused on the measurement of changes in circulating hormone levels.

In these research settings, data show patterns related to the primary outcome of preventing pregnancy. These findings contribute to the broader evidence landscape used in regulatory review. Pharmacodynamic studies described patterns related to the inhibition of ovulation, which was observed in some studies following administration. Trials tracked patterns of subject discontinuation and studies report how symptoms evolved in the observed populations, including the tracking of acceptability and continuation rates. Additionally, trials reported measurements of changes in menstrual bleeding profiles, which often described patterns of irregular bleeding over the 12-month study periods.

Long-Term Research and Follow-up Duration

Clinical trials typically observed responses over defined time intervals, with most formal studies evaluating the product’s evaluation and patient experience over 12 consecutive menstrual cycles (approximately one year). This duration provides context for short-to-medium-term changes.

Research has also explored longer-term outcomes related to the recovery of physiological function after treatment cessation. Longer observation periods, sometimes up to 60 months, are available from retrospective and post-marketing experience analyses. A key outcome was evaluated in studies tracking the time required for the return to pre-treatment fertility status after treatment cessation. However, the comprehensive long-term effects are not fully established by prospective, controlled trials beyond the intermediate term.

Consistency and Specificity in Study Populations

The evidence examined populations consisting of women of reproductive age, with study enrollment commonly focused on individuals between 15 and 38 years old. These individuals were seeking a sustained, reversible method of contraception.

The evidence quality varies across studies, and many of the original foundational research reports for this specific combination research describes cohorts primarily from regionally concentrated populations, especially in Latin America. These findings apply only to the populations studied, meaning that data for certain groups remain insufficient or were not included in the main clinical evaluations.

Research Quality, Consistency, and Key Limitations

The research evidence base for Femvulen is coarsely graded as High for the evaluation of short-to-medium term contraceptive outcomes, based on the consistency of the findings in the observed populations. The body of evidence for these outcomes is coarsely graded as Moderate for longer-term and specific secondary outcomes, such as changes in bleeding patterns.

Research limitation frames indicate that many of the original studies are older, originating from the 1970s and 1990s. Furthermore, comparative evidence is lacking in terms of recent, large-scale randomized controlled trials (RCTs) that directly compare this specific formulation against other formulations included in the broader research landscape. This limits the ability of the evidence to contextualize its findings relative to other formulations. Long-term effects are not fully established by prospective trials.

Common questions about Femvulen (FAQ)

---

Q: How is Femvulen different from other similar medicines I've seen advertised?

A: Official information describes Femvulen as a Combined Injectable Contraceptive (CIC). The characteristics of the formulation define it as an oil-based solution intended specifically for intramuscular injection, requiring administration on a monthly schedule. This route and frequency of use differentiate it from daily oral pills or other formulations.

Q: Is it necessary to avoid alcohol completely while using Femvulen?

A: While the labeling focuses on drug-drug interactions, official product information may include notes about alcohol consumption. Guidance often suggests that excessive acute alcohol use may lead to higher levels of circulating estradiol (one of the active ingredients).

Q: Are there any specific vitamins or supplements that are known to interact with Femvulen?

A: The official labeling explicitly notes that the herbal supplement St. John’s Wort is a known hepatic enzyme inducer. Official labeling notes that the use of St. John's Wort with this medicine is advised against, as it may reduce the effectiveness of Femvulen. Information on other vitamins is generally not specifically detailed.

Q: Is Femvulen available in different strengths or forms?

A: Official documents define the product as a specific oil-based solution for intramuscular injection. Regulatory documents specify a single standard formulation containing a fixed combination of active ingredients. Other strengths or non-injectable forms are not typically described in the standard labeling.

Q: Does Femvulen contain any ingredients that commonly cause allergic reactions?

A: Regulatory documents list all active ingredients and inactive components, also known as excipients, including the oil-based vehicle used for the injection. Individuals with known allergies to any component listed in the official description should refer to the full labeling.

Q: How quickly does Femvulen leave the body after the last use?

A: Due to the depot injection system, the active ingredients are released and gradually eliminated from the body over time. Studies tracking the return of pre-treatment hormonal patterns, such as the return to fertility, often observe subjects over a period of several months after the last injection.

Q: How does Femvulen work in the body at a high level?

A: The primary intended effect described in official documents is providing contraception (pregnancy prevention). This is achieved through the combined hormonal action, which includes the suppression or inhibition of ovulation.

Q: Does the time of day I use Femvulen matter?

A: The critical element of the usage protocol is maintaining a strict monthly injection interval, such as every 30 pm 3 days. Regulatory documents do not typically specify a particular time of day for the intramuscular injection, provided the overall monthly schedule is maintained.

Q: Is Femvulen ever prescribed for individuals under the age of 18?

A: The drug is indicated for use in females of reproductive potential. Clinical trial evidence often includes young women starting at age 15. The official labeling contains specific sections detailing its use and safety considerations in this age group, known as pediatric use.

Q: What happens if I forget to use Femvulen for a day or two?

A: Official instructions provide specific guidance for a missed dose or deviation from the scheduled monthly injection interval. This guidance typically outlines when a backup non-hormonal method of contraception may be required to maintain protection.

Q: Is Femvulen a medicine that needs to be taken long-term?

A: The medication is designed and indicated for use as a continuous method of contraception. It is generally intended to be used for as long as the user requires pregnancy prevention.

Q: How long does it typically take before I start noticing any effect from Femvulen?

A: Regulatory documents state that contraceptive effectiveness begins after the initial injection. Official guidance for the initial administration outlines the need for a backup non-hormonal method for the first seven days if the start is not on Day 1 of the cycle, reflecting the time needed to establish protection.

Q: What is the expected duration of the effects of Femvulen after a dose?

A: The duration of effect is directly tied to the strict monthly administration schedule. The injection formulation is specifically designed to provide and maintain therapeutic levels of the hormones for the full duration of the 30-day interval before the next scheduled injection.

Q: What should I do if I experience a mild, non-serious side effect?

A: Official safety documents list the known side effects and categorize them by frequency and severity. Official safety documents indicate the importance of reporting any symptoms or side effects experienced while using the drug.

Q: Can individuals with existing kidney problems be prescribed Femvulen?

A: Official labeling typically includes a section on the use of the medicine in people with renal (kidney) impairment. This may state that no specific studies were conducted in this group or advise caution, as the elimination of estrogen is partially dependent on kidney function.

Q: Has there been research on how Femvulen affects quality of life?

A: Clinical research evidence examined in the regulatory review did track certain experience measures that are related to quality of life. These measures included subject continuation rates in the trials and the general acceptability of the drug within the study populations.

Q: Are there clinical trials still ongoing for new uses of Femvulen?

A: Information on new or ongoing research into different uses for Femvulen is publicly available through official regulatory-affiliated databases. These include resources such as the NIH Clinical Trials database or the EMA Public Register.

Q: Is Femvulen available as a generic version?

A: Official sources, such as regulatory records (like the FDA Orange Book), identify whether an Authorized Generic or a generic equivalent version of the drug has been approved for the same formulation.

Q: Are there any specific monitoring tests required when taking Femvulen long-term?

A: Official labeling requires periodic monitoring of specific health parameters for certain users. For example, individuals with prediabetes or diabetes require monitoring of glucose tolerance, and those with hypertension require regular blood pressure monitoring.

Q: Do studies exist that compare Femvulen's effectiveness in different age groups?

A: Clinical research applies only to the populations studied, which were women of reproductive age (commonly between 15 and 38 years old). Regulatory documents note that comparative evidence against other hormonal formulations is generally lacking.

Q: What is the risk of dependence or withdrawal symptoms associated with Femvulen?

A: Official labeling, in sections addressing drug abuse and dependence, typically states that no potential for dependence or abuse has been established for this type of hormonal contraceptive.

Q: Is Femvulen known to cause any skin reactions or rashes?

A: Official documents list Acne as one of the common adverse reactions reported in clinical trials. Any more generalized skin reaction or rash would be documented in the safety sections if reported by regulatory authorities.

Q: What is the typical age range of people using Femvulen?

A: The medicine is indicated for use in females of reproductive potential. The clinical studies used to evaluate its safety and effectiveness focused on women generally between the ages of 15 and 38.

Q: If I am taking multiple medicines, how can I check for potential interactions with Femvulen?

A: The full list of known or potential interactions is contained within the official regulatory documents, which are accessible to the public and healthcare professionals for review and consultation.

Q: Are there common mental health or mood-related side effects linked to Femvulen?

A: Official documents list Mood Swings as a common adverse reaction reported in clinical trials. Users are encouraged to consult the official labeling for a complete list of reported symptoms.

Q: Do official documents mention any potential for overdose with Femvulen?

A: Official product information contains a specific section addressing Overdosage. This section describes what happens if too much of the drug is administered and any associated symptoms that may occur.

How to Store and Dispose of Femvulen

The official labeling for Femvulen (Algestone Acetophenide/Estradiol Injectable Solution) defines specific environmental and handling rules that must be followed to maintain the product's integrity.

Storage Classification	Requirement
Temperature	Store at Controlled Room Temperature (typically 20°C to 25°C).
Protection	Protect from light and keep the product in its original outer carton.
Prohibited Conditions	Do not freeze and do not use the solution if it appears cloudy, discolored, or contains particles.
Safety	The product must be kept out of the sight and reach of children.

Used needles and syringes must be discarded immediately into a government-compliant sharps disposal container. Unused or expired medication must not be thrown in household trash or poured down the sink or toilet but should be taken to a designated pharmaceutical drug take-back program.